CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

NCT01964378 ↗

Phase 3 Terminated 200 enrolled Tris Pharma, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release (PR).

Timeline

Start: 2013-10-29
Primary completion: 2015-10-16
Completion: 2015-10-16

Publications

Results Eerdekens MH, Kapanadze S, Koch ED, Kralidis G, Volkers G, Ahmedzai SH, Meissner W. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. Eur J Pain. 2019 Mar;23(3):577-588. doi: 10.1002/ejp.1331. Epub 2019 Jan 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cebranopadol	Small molecule	200 ug	Oral
Subject	Cebranopadol	Small molecule	400 ug	Oral
Subject	Cebranopadol	Small molecule	600 ug	Oral
Subject	Cebranopadol	Small molecule	1000 ug	Oral
Comparator	Morphine Prolonged Release	Unknown	15 mg	Oral
Comparator	Morphine Prolonged Release	Unknown	30 mg	Oral
Comparator	Morphine Prolonged Release	Unknown	45 mg	Oral
Comparator	Morphine Prolonged Release	Unknown	150 mg	Oral

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

Summary

Timeline

Publications

Drugs

Indications